Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular tag pinpoints which breast cancer tumors are most likely to spread

14.11.2002


A new molecular tag discovered by scientists at The University of Texas M. D. Anderson Cancer Center may help doctors decide which breast cancer patients need more aggressive treatment and which can forego the potentially toxic course of chemotherapy.



Khandan Keyomarsi, Ph.D., associate professor in experimental radiation at M. D. Anderson, and her colleagues report in the November 14, 2002, issue of the New England Journal of Medicine that high levels of a protein called cyclin E are closely associated with aggressive, invasive breast cancer. The study, conducted with tissue samples of current or former breast cancer patients, appears to show that cyclin E is a much better predictor of patient outcome than any current predictive marker. However, says Keyomarsi, the study must be repeated with newly diagnosed patients to determine its true predictive value.

The ability to predict which breast cancer tumors will recur or spread throughout the body is an important aspect of breast cancer treatment, says Keyomarsi. Currently, the prognosis for women diagnosed with breast cancer is determined by whether tumor cells have spread to lymph nodes. But some women who have cancer cells in the lymph nodes never have a recurrence, while others whose cancer has not spread do have a recurrence. Yet many women, after discussions with their doctors, opt to undergo grueling chemotherapy in hopes of ensuring any rogue cancer cells that may be present are killed. If an accurate predictive marker were available, many women could be spared chemotherapy, she says.


In the study, Keyomarsi and her colleagues looked for the presence of cyclin E because when this protein is present at high levels inside cancer cells it signals cells to multiply all the time. In normal cells, cyclin E is present only for a short time and helps keep cell division under tight control. In addition, the scientists discovered smaller versions of cyclin E that are not present in normal cells. These low molecular weight versions are generated by an enzyme that chops up the normal cyclin E and in the process creates a new form that is even better at signaling cells to divide.

"We have shown the occurrence of low molecular weight forms of cyclin E that are not found in normal cells and are present throughout cell cycle in cancer cells," says Keyomarsi. "These abnormal forms of cyclin E are always giving the ’go’ signal, telling cells to divide."

The scientists examined tumor tissue from 395 patients with breast cancer. Of those patients with stage one breast cancer, in which a single tumor is found and the cancer has not yet spread, about 10 percent had high levels of cyclin E in their cancer cells. All of these patients had died from a recurrence of breast cancer within five years of diagnosis, while none of the patients who had low levels of cyclin E had died. The proportion of tumors that had high levels of cyclin E increased with increasing extent of disease.

"This study shows that the presence of low molecular weight forms of cyclin E has a very powerful prognostic value," says Keyomarsi. "However, we have to validate the study using newly diagnosed patients in which we are blinded to the diagnosis. We are in the midst of that study now. If it bears out our initial results, we will try to get it into the clinic as soon as possible, though it may be at least one year."

Keyomarsi points out, however, that the specialized laboratory technique, called a western blot, used in her study is not available in most clinical laboratories that test patient samples. In order for the results to be used, testing laboratories would need to learn how do use the new technique.

"My hope is that this technique may help ease the burden of chemotherapy among breast cancer patients," says Keyomarsi. "Women who don’t overexpress cyclin E may not need chemotherapy, which kills all dividing cells and can do significant damage to other tissues and organs."

For those patients who have high levels of cyclin E more aggressive treatment would be indicated, she says. And intensive research is now underway at M. D. Anderson to find ways to stop production or block cyclin E in those patients where it is present.


Keyomarsi’s research was supported by grants from the U.S. Army Medical Research and Material Command and the National Cancer Institute. Dr. Keyomarsi holds U.S. patents (#5,543,291 and #5,763,219) on the use of cyclin E to detect and treat cancer.

Laura Sussman | EurekAlert!

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

Im Focus: Small collisions make big impact on Mercury's thin atmosphere

Mercury, our smallest planetary neighbor, has very little to call an atmosphere, but it does have a strange weather pattern: morning micro-meteor showers.

Recent modeling along with previously published results from NASA's MESSENGER spacecraft -- short for Mercury Surface, Space Environment, Geochemistry and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

Conference Week RRR2017 on Renewable Resources from Wet and Rewetted Peatlands

28.09.2017 | Event News

 
Latest News

A single photon reveals quantum entanglement of 16 million atoms

16.10.2017 | Physics and Astronomy

The melting ice makes the sea around Greenland less saline

16.10.2017 | Earth Sciences

On the generation of solar spicules and Alfvenic waves

16.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>